Product Images Memantine Hydrochloride

Each extended-release capsule contains T Memanine hydrochioride USP 14 mg. The usual dosage can be found in the package insert for once-daily use. Store Memantine at 20° to 25°C (68°F to 77°F) and keep it in a tightly closed container as described in the USP. This medication should be kept out of reach of children. The brand responsible for this product is Macicoids PharmaUSA, Inc. and it comes in a package of 30 capsules.*

This product is a package of Memantine Hydrochloride Extended Release Capsules with a dosage of 10mg. The capsules are designed for once daily use. Each box contains 100 capsules.*

Each extended-release capsule contains Memantine hydrochloride USP 21 mg. The usual dosage can be found in the package insert along with full prescribing information. This medication should be stored in a closed container at temperatures between 15 to 30 degrees Celsius (58 to 86 degrees Fahrenheit). The capsules are to be kept out of reach of children. This pharmaceutical product is from Macleods Pharma USA, Inc.*

This is a product description for Memantine Hydrochloride Extended Release Capsules. The medication is available in a 28 mg strength and comes in a pack of 100 capsules (10 x 10 unit doses) for once daily use. The packaging also includes the NDC number 33342-222-12. The text might contain additional information or instructions regarding the usage and storage of the medication.*

This text provides information on an extended-release capsule containing 28 mg of Memantine Hydrochloride USP. It also mentions the usual dosage instructions, storage conditions, and details about the manufacturer. Additionally, it includes a caution to keep the drug out of reach of children and provides contact details for the manufacturer.*

This is a product label for Memantine Hydrochloride Extended-Release Capsules, each capsule containing 7mg of Memantine hydrochloride USP. The usual dosage and storage instructions are provided, including recommended temperature ranges for storage. The manufacturer is listed as Macleods Pharma USA, Inc. Keep this medication and all drugs out of the reach of children.*

Mean (+ SEM) Change from Baseline in SIB Score from a study comparing the effects of Memantine HCI ER 28 mg/AChEI to Placebo/AChEI over 12 weeks of treatment. The graph shows data points at 16, 20, and 24 weeks, illustrating the clinical decline.*

This text appears to show a graph or chart representing the cumulative percentage of patients at different levels. It includes data for Memantine HCI ER 28 mg/AChEI and Placebo/AChEI. The graph might be related to changes in SIB (Severe Impairment Battery) scores from baseline.*

The text is not-readable.*

This is a chart showing the percentage of patients experiencing different levels of improvement or worsening while taking Memantine HCI ER 28 mg/AChEI compared to Placebo/AChEI in a study. The levels of improvement are categorized as Marked, Moderate, and Minimal Improvement, as well as No Change. Similarly, levels of worsening are categorized as Minimal, Moderate, and Marked Worsening based on CIBIC Plus ratings.*